SeaStar Medical Reaches Milestone of 100th QUELIMMUNE Commercial Device as Shipments Begin to its Third Hospital Customer
15. November 2024 08:30 ET
|
SeaStar Medical Holding Corporation
DENVER, Nov. 15, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of...
SeaStar Medical Adds Second Hospital Customer for QUELIMMUNE
31. Oktober 2024 08:30 ET
|
SeaStar Medical Holding Corporation
DENVER, Oct. 31, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of...
Economic Analysis Supporting Significant Hospitalization Cost Reduction with SeaStar Medical’s QUELIMMUNE Pediatric Therapeutic Device Presented at ASN Kidney Week 2024 - Update
25. Oktober 2024 11:32 ET
|
SeaStar Medical Holding Corporation
Data illustrate the potential of QUELIMMUNE™️ with cost neutrality starting at 6 days of therapy and a significant reduction in total hospitalization costs in children with acute kidney injury ...
Economic Analysis Supporting Significant Hospitalization Cost Reduction with SeaStar Medical’s QUELIMMUNE Pediatric Therapeutic Device Presented at ASN Kidney Week 2024
25. Oktober 2024 08:30 ET
|
SeaStar Medical Holding Corporation
Data illustrate the potential of QUELIMMUNE™️ with cost neutrality starting at 6 days of therapy and a significant reduction in total hospitalization costs in children with acute kidney injury ...
SeaStar Medical to Webcast Fireside Chat at the H.C. Wainwright Global Investment Conference
05. September 2024 08:00 ET
|
SeaStar Medical Holding Corporation
DENVER, Sept. 05, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of...
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of SeaStar
29. August 2024 19:12 ET
|
Faruqi & Faruqi LLP
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In SeaStar To Contact Him Directly To Discuss Their Options If...
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of SeaStar
22. August 2024 20:13 ET
|
Faruqi & Faruqi LLP
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In SeaStar To Contact Him Directly To Discuss Their Options ...
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of SeaStar
15. August 2024 11:05 ET
|
Faruqi & Faruqi LLP
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In SeaStar To Contact Him Directly To Discuss Their Options ...
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of SeaStar
02. August 2024 11:20 ET
|
Faruqi & Faruqi LLP
If you suffered losses exceeding $50,000 investing in SeaStar stock or options between October 31, 2022 and March 26, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner...
First Pediatric Patient Treated in a Commercial Setting with SeaStar Medical’s FDA-Approved QUELIMMUNE Therapeutic Device
23. Juli 2024 08:30 ET
|
SeaStar Medical Holding Corporation
DENVER, July 23, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (SeaStar Medical) reports treatment of the first patient in a commercial setting with QUELIMMUNE™, its...